title: Metastatic bladder cancer: a review of current management.
abstract: Bladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies.
authors.affiliation: Department of Palliative and Supportive Care, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Fletcher
authors.forename: Ananya
authors.initials: A
authors.lastname: Choudhury
authors.forename: Nooreen
authors.initials: N
authors.lastname: Alam
references.citation: J Natl Cancer Inst. 2005 Jun 1;97(11):798-804
references.pmid: 15928300
references.citation: J Clin Oncol. 1998 Jun;16(6):2038-44
references.pmid: 9626201
references.citation: Lancet Oncol. 2010 May;11(5):459-64
references.pmid: 20378407
references.citation: Radiother Oncol. 1999 Aug;52(2):101-9
references.pmid: 10577695
references.citation: Minerva Urol Nefrol. 2009 Mar;61(1):1-8
references.pmid: 19417721
references.citation: J Clin Oncol. 2011 Apr 20;29(12):1525-30
references.pmid: 21422406
references.citation: J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12
references.pmid: 7563203
references.citation: Radiother Oncol. 1997 May;43(2):171-4
references.pmid: 9192963
references.citation: J Clin Oncol. 2006 Jul 20;24(21):3451-7
references.pmid: 16849761
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4454-61
references.pmid: 19687335
references.citation: Clin Adv Hematol Oncol. 2007 Jun;5(6):456-8
references.pmid: 17679920
references.citation: Eur Urol. 2005 Nov;48(5):771-5; discussion 775-8
references.pmid: 16126330
references.citation: Cancer. 2004 Apr 15;100(8):1639-45
references.pmid: 15073851
references.citation: Invest New Drugs. 2007 Apr;25(2):181-5
references.pmid: 16983508
references.citation: Ann Oncol. 2007 Aug;18(8):1359-62
references.pmid: 17693649
references.citation: Int J Clin Pract. 2006 Jan;60(1):27-31
references.pmid: 16409425
references.citation: J Clin Oncol. 2005 May 20;23(15):3314-21
references.pmid: 15738536
references.citation: Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):379-88
references.pmid: 10802363
references.citation: Radiother Oncol. 1999 Aug;52(2):111-21
references.pmid: 10577696
references.citation: Eur Urol. 2007 Jul;52(1):134-41
references.pmid: 17207911
references.citation: Urol Int. 2008;80(1):13-8
references.pmid: 18204227
references.citation: Int J Clin Oncol. 2010 Aug;15(4):382-9
references.pmid: 20354750
references.citation: Cancer. 2009 Jul 1;115(13):2881-90
references.pmid: 19399906
references.citation: J Clin Oncol. 2001 May 15;19(10):2638-46
references.pmid: 11352955
references.citation: Clin Genitourin Cancer. 2009 Aug;7(2):E28-33
references.pmid: 19692319
references.citation: Ann Oncol. 2008 May;19(5):946-50
references.pmid: 18272914
references.citation: J Clin Oncol. 2000 Sep;18(17):3068-77
references.pmid: 11001674
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2218-24
references.pmid: 17538166
references.citation: J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
references.pmid: 15173273
references.citation: Cochrane Database Syst Rev. 2004;(2):CD004721
references.pmid: 15106258
references.citation: Cancer. 1997 Nov 15;80(10):1966-72
references.pmid: 9366300
references.citation: J Clin Oncol. 1998 Feb;16(2):593-602
references.pmid: 9469347